| Date | Time | Source | Headline | Symbol | Company |
| 06/14/2024 | 6:07AM | iHub Newswire | FeaturedFifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates | | |
| 06/10/2024 | 8:30AM | PR Newswire (US) | Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 05/30/2024 | 6:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 05/29/2024 | 8:45AM | PR Newswire (US) | Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 05/29/2024 | 8:30AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 05/22/2024 | 5:42PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 05/21/2024 | 8:45AM | PR Newswire (US) | MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 05/20/2024 | 8:00AM | PR Newswire (US) | Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 05/13/2024 | 4:31PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 04/02/2024 | 8:00AM | PR Newswire (US) | Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 03/21/2024 | 11:04AM | PR Newswire (US) | MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 03/07/2024 | 4:45PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 02/05/2024 | 8:30AM | PR Newswire (US) | MIRA Pharmaceuticals Provides Corporate Update | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 01/17/2024 | 4:30PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 12/28/2023 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 12/27/2023 | 5:33PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 12/27/2023 | 5:27PM | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 12/18/2023 | 4:50PM | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 12/04/2023 | 8:00AM | PR Newswire (US) | MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 12/01/2023 | 5:00PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 11/29/2023 | 8:00AM | PR Newswire (US) | MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80% | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 11/21/2023 | 10:42AM | PR Newswire (US) | MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 11/21/2023 | 10:09AM | PR Newswire (US) | MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 11/20/2023 | 4:18PM | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 11/20/2023 | 4:15PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 11/20/2023 | 8:10AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 11/20/2023 | 8:00AM | PR Newswire (US) | MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2 | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 09/18/2023 | 8:30AM | PR Newswire (US) | MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 09/05/2023 | 8:31AM | PR Newswire (US) | MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 08/31/2023 | 8:31AM | PR Newswire (US) | MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |